Allen Chiang, MD
Ophthalmology · Plymouth Meeting, PANPI 1326212960
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,509 of the $18,963 with a category attached, or 76.5%. F. Hoffmann-la Roche AG accounts for 76.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $14,574 and has fallen 99.6% since, to $53 in 2024. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1354.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$15K
- Genentech USA, Inc.$2K
- Genentech, Inc.$2K
- Boston Scientific$53
Across 231 payments — averaging $6877.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$1M
- Genentech, Inc.$459K
- Regeneron$71K
- F. Hoffmann-la Roche AG$10K
What the payments were for
- Consulting fees$4,33523%
- Speaking & faculty fees$14,50977%
- Food & beverage$1191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 9 | $14,509 |
| Genentech USA, Inc. | 2 | $2,413 |
| Genentech, Inc. | 2 | $1,988 |
| Boston Scientific | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$18,844
How this compares
$18,963 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 113 | $6,351 |
| ProlensaBromfenac Sodium | 18 | $5,993 |
| Bromfenac Sodium | 17 | $2,399 |
| Ketorolac Tromethamine | 81 | $1,262 |
| Atropine Sulfate | 12 | $594 |
| Brimonidine Tartrate | 22 | $572 |
| Ofloxacin | 23 | $377 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $273 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 14 | $91 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.